Cell News and Research

RSS

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

A newly awarded U.S. Patent will protect TechniScan, Inc's., novel way to image, biopsy and treat breast cancer.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

Adults with SCA show poorer performance on neurocognitive tests: Study

Compared with a group of healthy study participants, adults with sickle cell anemia showed poorer performance on neurocognitive tests, which was associated with anemia and age, according to a study in the May 12 issue of JAMA.

13 May 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.

13 May 2010

Research investigates MDR in human HCC

Hepatocellular carcinoma responds poorly to chemotherapy owing to MDR. Recent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers.

13 May 2010

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Fortis Hospitals Mulund, Mumbai, performed a multiple joint replacement surgery on a 27 year old young Nigerian patient. Rebacca underwent a hip and a shoulder replacement surgery by Dr. Sachin Bhonsle, Consultant Orthopedic Surgeon, after years of suffering in pain and immobility.

13 May 2010

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

In 1985 there was little hope for people with AIDS. Newspapers and television screens were filled with ghastly pictures of emaciated figures dying from a disease that had no cure.

13 May 2010

Four caged xanthones can inhibit growth of CCA cell lines: Research article

Cholangiocarcinoma is a malignant tumor, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents. Therefore, searching for novel and effective therapeutic agents for CCA is necessary. In previous studies, several caged xanthones from G. hanburyi have been reported to be potent antiproliferatives as well as having anticancer and anti-tumor activities and they induce apoptosis in various cancer cell lines.

13 May 2010

Individual's lifestyle choices can affect cholesterol, triglycerides levels: Mayo Clinic Health Letter

Diet and lifestyle choices aren't only evident on the bathroom scale. The effect of these choices is also reflected with relative accuracy in cholesterol numbers.

13 May 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

Tobacco-free cigarettes may be more carcinogenic than tobacco products: Study

Using the same technique they developed to document the harmful effects of tobacco products, a team of researchers found that cigarettes made without tobacco or nicotine may be more carcinogenic because they actually induce more extensive DNA damage than tobacco products.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

Tracking genes in infant's intestine helps compare early development of breast-fed and formula-fed babies

Is breast milk so different from infant formula? The ability to track which genes are operating in an infant's intestine has allowed University of Illinois scientists to compare the early development of breast-fed and formula-fed babies. They say the difference is very real.

13 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the first quarter, ended March 31, 2010.

12 May 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 third quarter, ended March 31, 2010.

12 May 2010

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.

12 May 2010

Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs, RNAi

Investigators from around the country came to Sanford-Burnham Medical Research Institute (Sanford-Burnham) on Friday, May 7, to share their knowledge of the burgeoning young field of microRNAs. These small non-coding nucleic acids turn off proteins and have been implicated in viral infection, cancer, cardiovascular disease, HIV and numerous other conditions.

12 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

Cell News and Research

Chimerix commences first-in-human study of CMX157 for HIV

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Adults with SCA show poorer performance on neurocognitive tests: Study

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Research investigates MDR in human HCC

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

Four caged xanthones can inhibit growth of CCA cell lines: Research article

Individual's lifestyle choices can affect cholesterol, triglycerides levels: Mayo Clinic Health Letter

Additional benefits of LAIAs over long-acting human insulin not been proven

Tobacco-free cigarettes may be more carcinogenic than tobacco products: Study

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Tracking genes in infant's intestine helps compare early development of breast-fed and formula-fed babies

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs, RNAi

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News